NSECertificate under SEBI (Depositories and Participants) Regulations, 20187 Oct 2026 · 7 Oct 2026, 01:18 pm

Certificate under SEBI (Depositories and Participants) Regulations, 2018

Bal Pharma Limited · BALPHARMA

✦ AI Summary

Bal Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Bal Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026

Attachments (1)

📄

BALPHARMA1_07102026131801_Reg_74_Final_.pdf

pdf

Download →
View document text
To To Date: October 07, 2026 Listing Compliance Department BSE Limited National Stock Exchange of India Limited, 1st Floor, New Trading Ring, Exchange Plaza, 5th Floor, Plot No. C/2, G Block, Rotunda Building, P.J. Bandra Kurla Complex, Bandra (E), Towers, Mumbai-400051 Dalal Street, Mumbai – 400001 Symbol: BALPHARMA Scrip Code: 524824 Sub: Confirmation as per Regulation 74(5) of SEBI (DP) Regulations. Dear Sir/Madam, With reference to the above and based on the certificate enclosed herewith, received from our Registrar and Transfer Agent, MUFG Intime India Private Limited, we hereby confirm that the details of securities dematerialised/rematerialised during the quarter ended 30th September 2026 have been duly furnished to all the Stock Exchanges where the equity shares of the Company are listed, within the prescribed time limit. We further confirm that the share certificates received for dematerialisation, wherever applicable, have been duly verified, mutilated and cancelled, and the name of the relevant Depository has been substituted in the records of the Company as the registered owner, within 15 days from the date of receipt of the certificate of security. Please takes this intimation on your records Thanking You. For Bal Pharma Limited Shreepada ML Company Secretary and Compliance officer ICSI M No : A66681 Enclosure: As above MUFG Intime India Private Limited (Formerly Link Intime India Private Limited) CIN: U67190MH1999PTC118368 Registered Address: C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai - 400 083 Tel: +91 22 4918 6000 www.in.mpms.mufg.com Date: October 07,2026 Bal Pharma Limited 5th Floor Lakshmi Narayan Complex, 10/1 Palace Road Bengaluru, Chickpet, Bangalore South, Karnataka, India, 560053 Kind Attn: CS Shreepada ML – Company Secretary Dear Madam, Sub: Confirmation Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulation, 2018. In reference to the above captioned regulation, we hereby confirm that the securities received from the depository participants for dematerialisation during the quarter ended 30th September 2026 were confirmed to the depositories by us and that securities comprised in the said certificates have been listed on the stock exchanges where the earlier issued securities are listed. We hereby also confirm that the security certificates received for dematerialisation have been confirmed after due verification by the depository participant and the name of the depositories have been substituted in the register of members as the registered owner within the prescribed timelines. We request you to kindly take note of the above in your records. Thanking you, Yours faithfully, For MUFG Intime India Private Limited (Formerly Link Intime India Private Limited) [Deepak Tambe] Asst. Vice President MUFG Intime India Private Limited A Part of MUFG Corporate Markets, a division of MUFG Pension & Market Services